Medical Center, 133 patients with spirometry test results within 3 years were retrospectively identified. COPD were defined as pre-bronchodilator FEV1/FVC less than 0.7, and overall survival (OS) and PFS were analyzed according to the presence of COPD. Objective response rate was also compared between patients with or without COPD.
Conclusion:
In NSCLC patients treated with palliative pembrolizumab, spirometry-based COPD was associated with significantly longer OS and PFS. Identifying coexisting COPD could help predict better treatment outcome in NSCLC patients treated with ICIs. Background and Aims: Aberrant O-glycosylation represents a common feature during oncogenesis in various tumor types. Our previous high throughput RNA-seq analysis revealed that low expression of ST3GAL3 (ST3 β-Galactoside α-2,3-Sialyltransferase 3), an O-glycan related terminal sialyltransferase, was an independent prognostic marker for poor overall survival. Therefore, we conducted a pathway analysis to further elucidate the underlying molecular mechanism of ST3GAL3 expression in lung cancer cells.
Methods: Eighty-one (adenocarcinoma n = 44, squamous cell carcinoma n = 37) archived non-small cell lung cancer (NSCLC) surgical samples from 1996 to 2008 underwent genome-wide RNA-seq analysis. We conducted Gene Set Enrichment Analysis (GSEA) by comparing patients with ST3GAL3 low expression to those with high expression. Curated pathways including Reactome and Oncogenic pathways from MsigDB were examined for enrichment. Pathways were considered positively enriched by the criteria of nominal P < 0.05 and false discovery rate q < 0.25. To validate the results, we validated the pathway analysis in two independent NSCLC cohorts from public databases (TCGA-LUAD/ LUSC from the United States and GSE81089 from Europe).
Results: Reactome pathway analysis revealed gene sets involved in immune system interaction, cell surface interaction, and Semaphorin4D among lung cancer samples with ST3GAL3 low expression. Oncogenic pathways related to EGFR, ERB2, KRAS, RAF, MEK and TP53 mutation were enriched in samples with ST3GAL3 low expression. Validation was done in TCGA-LUAD/LUSC (n = 1019) and GSE81089 (n = 199). Immune system interaction and Toll-like receptor pathways were enriched in TCGA and GSE81089 cohorts. KRAS pathway enrichment was seen in both validation cohorts. EGFR, RAF, MEK and TP53 mutation-related pathways were also enriched in TCGA cohort.
We have identified interrelated cellular/immune interaction and oncogenic pathways with regard to ST3GAL3 low expression. Alterations in sialylation of receptors in these pathways may contribute to altered cancer cell behaviours. This provides further mechanistic targets for validation on the role of ST3GAL3 in prognostic and possibly therapeutic applications in NSCLC. Background and Aims: Lung cancer considered as leading cause of cancer related death all over the world. Epidermal Growth Factor Receptor (EGFR) mutation in lung adenocarcinoma influenced treatment options and prognosis. Metastasis in lung adenocarcinoma generally worsen the prognosis and patient's survival rates. This research aim to determine the effect of EGFR mutation to metastasis in lung adenocarcinoma patients.
Methods: Samples are stage IIIB-IV lung adenocarcinoma patients between January 2017 -February 2018 in Dr. Sardjito Hospital Yogyakarta. The patient then divided into EGFR mutation group and wild type group. The effect of EGFR mutation to metastasis will be determined retrospectively by Fisher's Exact Test, and odds ratio. The relation of demographical and clinical status to EGFR mutation will be determined by Logistic regression analysis. Then P value < 0.05 with confidence interval 95% considered as significant.
Results: Total of 71 lung adenocarcinoma patients consist of 26 (36,6%) patients with EGFR mutation (Exon 19, 20, and 21) and 45 (63,4%) wild type. The EGFR mutation frequency significantly higher in patients with 2 or more metastasis sites (50% vs 26.6%; P = 0,047, OR = 2.75). Further analysis to specific metastasis location showed that brain metastasis (11.53% vs 6.66%; OR = 1.82) and bone metastasis (30.76% vs 13.33%; OR = 2.88) are more frequent in EGFR mutation group than wild type group. Logistic regression analysis of EGFR mutation status to age, sex, performance score, and stage did not show any significance.
